Thc News

The U.S. Senate voted 61-32 on August 8 to reject an amendment that would have killed a delay of the looming federal hemp ban, pushing the shutoff date to December 11 and giving Minnesota's fast-growing hemp-derived THC industry a short but critical reprieve.

Migraines affect roughly 850,000 Minnesotans. Here is what clinical research says about cannabis for acute migraine relief and prevention, including drug interactions with triptans, beta-blockers, topiramate, and valproate, and how to qualify for the medical cannabis program.

Sleep problems are the most common reason Minnesotans visit a dispensary. Here is what the clinical evidence actually shows about THC, CBD, and CBN for insomnia, plus drug interactions and which qualifying conditions apply in Minnesota.

Depression affects millions of Minnesotans. This research-backed guide covers the endocannabinoid system's role in mood, what clinical studies actually show, how CBD and THC differ, drug interactions with antidepressants, and practical guidance for consumers in 2026.

The federal loophole that made delta-8, THCA, and hemp-derived THC products legal nationwide is closing. Here is what the Continuing Appropriations Act, 2026 means for Minnesota consumers, businesses, and the regulated dispensary market.

THC, CBD, CBN, CBG, CBC, THCV, here is what each cannabinoid actually does, how they interact with your body, and how to use this knowledge when shopping at Minnesota dispensaries in 2026.

Microdosing means taking 1 to 5mg of THC for therapeutic benefit without meaningful intoxication. Here is how to find your minimum effective dose, which products to use, and what Minnesota law says.

Chronic pain and intractable pain qualify for Minnesota's medical cannabis card. Here is what research supports, which products work best for different pain types, and how to use cannabis alongside conventional treatment.